A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer

Phase I/II data from Opdivo/Yervoy combination in SCLC provide more evidence that tumor mutation burden is emerging as a biomarker for immunotherapy, but commercial value is unclear and results don't have implications for the all-important CheckMate 227 non-small cell lung cancer trial, analysts say.

LungCancerCells_1200x675

Bristol-Myers Squibb Co.'s latest data for the combination of Opdivo and Yervoy suggest a role for the duo in a new indication for small cell lung cancer (SCLC) and generally give more support to the emerging biomarker of "tumor mutation burden" in guiding immunotherapy treatment.

PD-L1 expression has been the most commonly used biomarker for checkpoint inhibitor immunotherapies to date, but is a flawed measure...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards